Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

0
104
Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. jointly announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application of limertinib for the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated NSCLC.
[Innovent Biologics, Inc. (PR Newswire)]
Press Release